The agreement includes six injectable products to be filed for Health Canada approval through JAMP Pharma Group.
Caplin Point Laboratories announced that its subsidiary, Caplin Steriles, has entered into a strategic partnership with JAMP Pharma Group for six injectable products to be filed shortly in Canada. Some of these products have already been filed by Caplin Steriles in the USA.
Commenting on the transaction, Mr C. C. Paarthipan, Chairman of Caplin Point Laboratories Limited, said: We have targeted Canada as one of our key expansion areas in Regulated Markets and we are excited to work with ]AMP, one of the fastest growing companies in Canada. We are confident that we will be adding more products to this partnership in due course.